Axogen

Q2 FY2026 EarningsQ2 FY2026 results exceeded revenue expectations with $69.7M vs. $67.1M consensus, representing a 23.1% YoY increase. Adjusted EPS of $0.12 beat the $0.1186 mean estimate, although GAAP gross margin of 72.7% missed the 74.2% consensus due to a shift in product mix driven by >50% growth in the Breast segment. Management raised FY26 revenue guidance to at least $279M (24% growth), well above the previous trajectory, while maintaining a positive free cash flow outlook for the year.